Ac-SDKP Evidence Guide
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.
Our Take
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.
- Best for
- Anti-fibrotic mechanistic research, kidney and cardiac fibrosis models (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Cardiac Anti-Fibrosis: Level D, mostly non-human evidence - Animal studies consistently demonstrate reduction in cardiac fibrosis and improved ventricular function in models of hypertension, myocardial infarction, and diabetic cardiomyopathy.
- Renal Fibrosis Prevention: Level D, mostly non-human evidence - Preclinical evidence shows reduced renal interstitial fibrosis and preserved kidney function in models of chronic kidney disease and diabetic nephropathy.
- Hematopoietic Stem Cell Protection: Level C, includes human evidence - Early human studies and extensive preclinical work demonstrate protection of hematopoietic stem cells from chemotherapy-induced damage by maintaining quiescence.
Side Effects and Warnings
- No significant adverse effects reported in preclinical studies
- Theoretical hypotensive effect at high doses
- Very limited human safety data
- Not approved for clinical use
- Extremely short half-life limits practical application
- Endogenous levels are regulated by ACE; exogenous supplementation effects are not fully characterized
- All evidence is predominantly preclinical
Research Dosage References
- <strong>Subcutaneous injection</strong> - 100-800 mcg/kg/day - Continuous infusion or divided doses - Primarily studied via osmotic minipump in animal models. Rapid degradation by ACE necessitates continuous delivery or ACE inhibitor co-administration.
Mechanism of Action
Ac-SDKP exerts anti-fibrotic and protective effects through: 1. TGF-beta/Smad pathway inhibition: Blocks TGF-beta1-induced fibroblast activation and collagen synthesis by inhibiting Smad2/3 phosphorylation. 2. Hematopoietic stem cell regulation: Prevents premature entry of hematopoietic stem cells into S-phase, protecting them from cytotoxic damage. 3. Macrophage polarization: Promotes M2 anti-inflammatory macrophage phenotype, reducing inflammatory tissue damage. 4. Endothelial protection: Enhances endothelial cell function and promotes angiogenesis in ischemic tissues.
Legal Status
Ac-SDKP is a research compound not approved for clinical use in any country. It is not a controlled substance. Available for research purposes only.
Primary Sources
- N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction in rats. Hypertension, 2003.
- Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts. Circ Res, 2003.
- The role of Ac-SDKP in the anti-fibrotic mechanism of ACE inhibitors. Curr Opin Pharmacol, 2009.